Sorbitol

Polyol Sweeteners Global Strategic Industry Report 2024: Market to Reach $7.7 Billion by 2030 - Growing Use in Pharmaceutical Applications, Fueling Market Prospects - ResearchAndMarkets.com

Retrieved on: 
星期二, 五月 21, 2024

The global market for Polyol Sweeteners estimated at US$4.9 Billion in the year 2023, is projected to reach a revised size of US$7.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030.

Key Points: 
  • The global market for Polyol Sweeteners estimated at US$4.9 Billion in the year 2023, is projected to reach a revised size of US$7.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030.
  • Key applications of polyol sweeteners span across the food and beverage industry, where they are used as bulking agents and to improve texture.
  • The global market outlook is positive, with the growing demand for healthy, low-calorie foods and beverages fueling market expansion.
  • Competition within the polyol sweeteners market is robust, with manufacturers continuously innovating to meet consumer demands for healthier, enjoyable eating experiences.

Global Sugar Alcohols Strategic Research Report 2023-2024 & 2030 - Exploding Demand for Food Additives Triggers Massive Opportunities - ResearchAndMarkets.com

Retrieved on: 
星期四, 五月 16, 2024

The "Sugar Alcohols - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sugar Alcohols - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
  • The global sugar alcohols market is experiencing steady growth, driven by their use across diverse sectors, generating sustained opportunities.
  • Growing awareness about the benefits offered by sugar alcohols is enhancing their appeal and image as sugar-free sweeteners.
  • Sugar alcohols have gained popularity as alternatives to sugar, particularly in regions with increasing health consciousness.

Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results

Retrieved on: 
星期三, 三月 6, 2024

The FDA also noted that it is planning to hold an advisory committee meeting to discuss the application.

Key Points: 
  • The FDA also noted that it is planning to hold an advisory committee meeting to discuss the application.
  • Govorestat was previously granted Pediatric Rare Disease designation and will qualify for a Priority Review Voucher (PRV) upon approval.
  • The Company expects a decision by the EMA in the fourth quarter of 2024.
  • Full study results will be presented at an upcoming medical conference, along with results of the Diabetic Peripheral Neuropathy sub-study, which are still being analyzed.

Tate & Lyle Partners with Cryptobiotix: New ex-vivo study on low and no calorie sweeteners finds positive impact or no impact on human gut microbiota

Retrieved on: 
星期四, 二月 15, 2024

Tate & Lyle PLC (Tate & Lyle), a world leader in ingredient solutions for healthier food and drink, partnered with Cryptobiotix, pioneers in preclinical gastrointestinal research, on the study.

Key Points: 
  • Tate & Lyle PLC (Tate & Lyle), a world leader in ingredient solutions for healthier food and drink, partnered with Cryptobiotix, pioneers in preclinical gastrointestinal research, on the study.
  • The doses of low and no calorie sweeteners used were based on actual intakes, regulations and amounts that are generally included in foods and beverages during different timepoints.
  • Assessments of additional low and no calorie sweeteners, including allulose and erythritol, are being completed and details will be shared in due course.
  • The low and no calorie sweeteners studied for this paper included: Acesulfame potassium (aceK), maltitol, sorbitol, stevia, sucralose and tagatose.

Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

Retrieved on: 
星期四, 二月 15, 2024

The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.

Key Points: 
  • The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
  • Govorestat is a central nervous system penetrant Aldose Reductase Inhibitor, which blocks the conversion of glucose to sorbitol, and has previously been shown to reduce sorbitol levels in patients with SORD Deficiency.
  • We believe the results from the 12-month interim analysis confirm the role of sorbitol as a key driver of disease severity and progression over time.
  • A replay of the webcast will be available for 90 days on the Investors section of Applied Therapeutics’ website.

New ex-vivo study on low and no calorie sweeteners finds positive impact or no impact on human gut microbiota

Retrieved on: 
星期四, 二月 8, 2024

Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects

Key Points: 
  • Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects
    LONDON, Feb. 8, 2024 /PRNewswire/ - A new, first-of-its-kind study has identified unique and potentially beneficial interactions between certain low and no calorie sweeteners, including stevia, and the human gut microbiota.
  • The doses of low and no calorie sweeteners used were based on actual intakes, regulations and amounts that are generally included in foods and beverages during different timepoints.
  • Assessments of additional low and no calorie sweeteners, including allulose and erythritol, are being completed and details will be shared in due course.
  • The low and no calorie sweeteners studied for this paper included: Acesulfame potassium (aceK), maltitol, sorbitol, stevia, sucralose and tagatose.

Diabetic Tussin Reintroduces Sugar-Free Cold and Cough Solution for People with Diabetes

Retrieved on: 
星期三, 十一月 29, 2023

TARRYTOWN, N.Y., Nov. 29, 2023 /PRNewswire/ -- Today, Diabetic Tussin®, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves. This restock brings with it the Better Choices for Life mark from the American Diabetes Association® (ADA). This over-the-counter cold and cough solution returns just as the threat of a 'tripledemic' — when cases of COVID-19, flu, and RSV surge at the same time—looms over American households.

Key Points: 
  • TARRYTOWN, N.Y., Nov. 29, 2023 /PRNewswire/ -- Today, Diabetic Tussin®, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves.
  • This over-the-counter cold and cough solution returns just as the threat of a 'tripledemic' — when cases of COVID-19, flu, and RSV surge at the same time—looms over American households.
  • "Diabetic Tussin is an essential over-the-counter cold and cough solution for millions of Americans concerned about ingredients in other products that can raise blood sugar levels.
  • Made with the strongest sugar-free formula on the market, Diabetic Tussin Max allows consumers to effectively manage their cough and cold symptoms with the right ingredients.

Global Polyol Sweeteners Strategic Market Report 2023: A $7.5+ Billion Market by 2030 - Focus on Sorbitol, Xylitol, Mannitol, Maltitol, Isomalt - ResearchAndMarkets.com

Retrieved on: 
星期五, 九月 15, 2023

The global market for Polyol Sweeteners is undergoing significant growth, with the industry expected to flourish in the coming years.

Key Points: 
  • The global market for Polyol Sweeteners is undergoing significant growth, with the industry expected to flourish in the coming years.
  • Independent analysis reveals substantial market potential across various geographic regions, offering valuable insights into past, present, and future trends.
  • With applications ranging from Food & Beverage to Personal Care & Cosmetics, Pharmaceuticals, and more, the Polyol Sweeteners market is poised for impressive growth.
  • The Polyol Sweeteners market in the U.S. is estimated at US$1.2 Billion in the year 2022.

Applied Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
星期四, 八月 10, 2023

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • “In the second quarter we continued to advance our programs across Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy,” said Shoshana Shendelman, PhD, Founder, Chief Executive Officer, and Chair of the Board.
  • In June 2023, the Company presented baseline data at the 2023 Annual Meeting of the ADA from the ongoing Phase 3 ARISE-HF study of AT-001 (caficrestat) in Diabetic Cardiomyopathy (DbCM).
  • The Company expects topline data from the study in the fourth quarter of 2023.
  • Net loss for the second quarter of 2023 was $29.6 million, or $0.37 per basic and diluted common share, compared to a net loss of $25.9 million, or $0.96 per basic and diluted common share, for the second quarter 2022.

WHO expert cancer group states that the sweetener aspartame is a possible carcinogen, but evidence is limited – 6 questions answered

Retrieved on: 
星期五, 七月 21, 2023

The World Health Organization declared on July 14, 2023, that the widely used synthetic sweetener aspartame could be a “possible” carcinogen, or cancer-causing agent, on the basis of “limited evidence for cancer in humans.” But the agency also concluded that the currently available data does not warrant a change of the acceptable daily intake of aspartame at this time.

Key Points: 
  • The World Health Organization declared on July 14, 2023, that the widely used synthetic sweetener aspartame could be a “possible” carcinogen, or cancer-causing agent, on the basis of “limited evidence for cancer in humans.” But the agency also concluded that the currently available data does not warrant a change of the acceptable daily intake of aspartame at this time.
  • The Conversation asked chronic disease epidemiologist Paul D. Terry, public health scholar Jiangang Chen and nutrition expert Ling Zhao, all from the University of Tennessee, to put these seemingly contradictory findings into perspective based on the available scientific evidence.

1. Why is aspartame being classified as ‘possibly’ cancer-causing?

    • Because it is approximately 200 times sweeter than table sugar, smaller amounts of aspartame are added to foods, and they contribute considerably fewer calories.
    • NutraSweet and Equal are well-known brand names for aspartame sold in packages for individual use.
    • The International Agency for Research on Cancer, an entity within the WHO, evaluated findings from both human and animal studies of aspartame and cancer.

2. What are the current guidelines for aspartame consumption?

    • This amount of aspartame per day translates to approximately eight to 12 cans of soda, or approximately 60 packets of aspartame, for a person weighing 132 pounds (60 kilograms).
    • For a child weighing 33 pounds (15 kg), it translates to between two to three cans of aspartame-sweetened soda per day, or approximately 15 packets of aspartame.

3. Does the WHO’s new stance change that recommendation?

    • Independently of the expert panel on cancer, the food safety group also evaluated the available evidence and concluded that there was no “convincing evidence” from either animal or human studies that aspartame consumption causes adverse effects within the currently established daily limits.
    • It is important to note that people with the rare inherited disorder called phenylketonuria, or PKU, should avoid or restrict aspartame intake.

4. How can two consensus groups reach different conclusions?

    • It is not uncommon for scientific consensus groups to differ in how they classify risk based on the results of published studies, even if more than one of those consensus groups is affiliated with the same agency or parent organization.
    • Whereas the WHO’s expert cancer group’s stance may appear to be more worrisome than that of the committee on food safety, in fact, the latter’s “no convincing evidence” is consistent with the cancer group’s “limited evidence” classification.

5. How does aspartame compare to other sweeteners?

    • But, like aspartame, many of these sweeteners have been implicated in developing cancer.
    • This list includes acesulfame potassium, or Ace-K – a synthetic calorie-free sugar substitute – as well as sugar alcohols and even simple sugar.

6. So what should consumers do?

    • And, as noted by the Mayo Clinic, artificial sweeteners may play a beneficial role for some people who are seeking to manage their weight or control their sugar intake.
    • One thing is clear: Scientific studies on aspartame consumption will continue, and it will be important for both consumers and the research community to continue weighing potential risks.